TG-1101
Showing 1 - 25 of 473
Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis
- Ublituximab
-
Pasadena, California
- +7 more
Aug 19, 2022
B-Cell Lymphoma Trial in Heidelberg, Melbourne, Nedlands (TG-1801, Ublituximab)
Active, not recruiting
- B-Cell Lymphoma
- TG-1801
- Ublituximab
-
Heidelberg, Victoria, Australia
- +2 more
Jan 20, 2023
Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)
Recruiting
- Relapsing Multiple Sclerosis
- Ublituximab
-
Fort Collins, Colorado
- +1 more
May 26, 2023
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)
Active, not recruiting
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- TG-1701
- +2 more
-
East Melbourne, Victoria, Australia
- +7 more
Jan 20, 2023
CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
-
Fayetteville, Arkansas
- +4 more
Jan 20, 2023
Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Fort Myers, Saint Petersburg, Nashville (Ublituximab, Umbralisib)
Terminated
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
-
Fort Myers, Florida
- +2 more
Jul 20, 2022
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)
Terminated
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
- Venetoclax
- +3 more
-
Chicago, Illinois
- +2 more
Aug 19, 2022
Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ublituximab
- +4 more
-
Boston, Massachusetts
- +2 more
Aug 19, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)
Not yet recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazemetostat
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 31, 2022
Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL Trial in New York (Umbralisib, Ublituximab)
Recruiting
- Chronic Lymphocytic Leukemia
- +2 more
-
New York, New YorkWeill Cornell Medicine
Mar 29, 2022
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,
Terminated
- Non-Hodgkins Lymphoma
- +6 more
-
Huntsville, Alabama
- +1 more
May 5, 2022
Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)
Suspended
- Mantle Cell Lymphoma
- Acalabrutinib
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 7, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Ublituximab, Umbralisib, Venetoclax)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Ublituximab
- +2 more
-
Birmingham, Alabama
- +49 more
Jan 20, 2023
Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)
Completed
- Relapsing Multiple Sclerosis (RMS)
- Ublituximab
- +3 more
-
Phoenix, Arizona
- +12 more
Nov 11, 2021
Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)
Completed
- Relapsing Multiple Sclerosis (RMS)
- Ublituximab
- +3 more
-
Carlsbad, California
- +13 more
Nov 5, 2021
Mantle Cell Lymphoma Trial in Birmingham (Ublituximab, Umbralisib)
Recruiting
- Mantle Cell Lymphoma
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Sep 8, 2021
Relapsing Multiple Sclerosis (RMS) Trial in Worldwide (Ublituximab)
Enrolling by invitation
- Relapsing Multiple Sclerosis (RMS)
- Ublituximab
-
Pasadena, California
- +84 more
Mar 22, 2022
Chronic Lymphocytic Leukemia Trial in Israel, United States (Ublituximab, Ibrutinib)
Completed
- Chronic Lymphocytic Leukemia
-
Huntsville, Alabama
- +87 more
Apr 25, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Ublituximab, Umbralisib, Bendamustine)
Terminated
- Diffuse Large B-Cell Lymphoma
- +4 more
- Ublituximab
- +2 more
-
Birmingham, Alabama
- +167 more
Jul 20, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Concentration of BRIUMVIâ„¢ (Ublituximab) in Breast Milk
Not yet recruiting
- Relapsing Multiple Sclerosis
- No intervention
- (no location specified)
Nov 16, 2023
Immunoglobulin A Nephropathy, Glomerular Disease, IgAN Trial in Worldwide (Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649)
Active, not recruiting
- Immunoglobulin A Nephropathy
- +2 more
- Dose-Placebo
- +3 more
-
Birmingham, Alabama
- +92 more
Mar 24, 2022
Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)
Not yet recruiting
- Glioblastoma Multiforme of Brain
- CHM-1101 CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 19, 2022